Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Cancer Treatment Reviews

Volumn 40, Issue 3, 2014, Pages 445-456

  Heavey, Susan ^a   O'Byrne, Kenneth J ^a   Gately, Kathy ^a  

^a Dublin Molecular Medicine Centre   (Ireland)

Author keywords

Chemoresistance; Co targeted inhibition; Lung cancer; MEK; MTOR; NSCLC; PI3K; PI3K inhibition; PIK3CA; Radioresistance

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CELL SURFACE RECEPTOR; DACTOLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS;

CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; DRUG CLASSIFICATION; DRUG TARGETING; HUMAN; IMMUNE EVASION; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; PATIENT IDENTIFICATION; RADIOSENSITIVITY; REVIEW;

CHEMORESISTANCE; CO-TARGETED INHIBITION; LUNG CANCER; MEK; MTOR; NSCLC; PI3K; PI3K INHIBITION; PIK3CA; RADIORESISTANCE;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84892901087     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.08.006     Document Type: Review

References (171)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Pfannschmidt J., Muley T., Bulzebruck H., Hoffmann H., Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007, 55:371-377.
3. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
4. Yamamoto H., Shigematsu H., Nomura M., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68:6913-6921.
5. Hoeflich K.P., Merchant M., Orr C., et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012, 72:210-219.
6. Whitman M., Kaplan D.R., Schaffhausen B., Cantley L., Roberts T.M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985, 315:239-242.
7. Ji M., Guan H., Gao C., Shi B., Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 11:147.
8. Philp A.J., Campbell I.G., Leet C., et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001, 61:7426-7429.
9. Taniguchi C., Winnay J., Kondo T., et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res 2010, 70:5305-5315.
10. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
11. Sanders H., Albitar M. Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genet Cytogenet 2010, 203:7-15.
12. Courtney K., Corcoran R., Engelman J. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
13. Okudela K., Suzuki M., Kageyama S., et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007, 57:664-671.
14. Karakas B., Bachman K., Park B. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459.
15. Kawano O., Sasaki H., Endo K., Suzuki E., Haneda H., Yukiue H., et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54:209-215.
16. Zhong D., Guo L., de Aguirre I., et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006, 53:285-294.
17. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367:1596-1606.
18. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
19. Crowder R.J., Phommaly C., Tao Y., et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009, 69:3955-3962.
20. Wee S., Wiederschain D., Maira S.M., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008, 105:13057-13062.
21. Ali K., Camps M., Pearce W., et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol. 2008, 180:2538-2544.
22. Durand C., Hartvigsen K., Fogelstrand L., et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009, 183:5673-5684.
23. Guo H., Samarakoon A., Vanhaesebroeck B., Malarkannan S. The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med 2008, 205:2419-2435.
24. Foukas L., Berenjeno I., Gray A., Khwaja A., Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 2010, 107:11381-11386.
25. Luk S., Piekorz R., Nürnberg B. Tony To S-S. The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion. Eur J Cancer 2012, 48:149-157.
26. Utermark T., Rao T., Cheng H., et al. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 2012, 26:1573-1586.
27. Carpenter C.L., Auger K.R., Chanudhuri M., et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993, 268:9478-9483.
28. Alessi D.R., James S.R., Downes C.P., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261-269.
29. Marsit C., Zheng S., Aldape K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36:768-776.
30. O'Byrne K., Gatzemeier U., Bondarenko I., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12:795-805.
31. Spoerke J., O'Brien C., Huw L., et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012, 18:6771-6783.
32. Balsara B.R., Pei J., Mitsuuchi Y., et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
33. Malanga D., Scrima M., De Marco C., et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008, 7:665-669.
34. Do H., Solomon B., Mitchell P., Fox S., Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008, 1:14.
35. Bleeker F., Felicioni L., Buttitta F., et al. AKT1E17K in human solid tumors. Oncogene 2008, 27:5648-5650.
36. Altomare D., Testa J. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
37. Guo Y., Du J., Kwiatkowski D. Molecular dissection of AKT activation in lung cancer cell lines. Mol Cancer Res 2013, 11(3):282-293.
38. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
39. Gately K., Al-Alao B., Dhillon T., et al. Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer 2012, 75:217-222.
40. Dobashi Y., Watanabe Y., Miwa C., Suzuki S., Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011, 4:476-495.
41. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008, 415:333-344.
42. Meylan E., Dooley A.L., Feldser D.M., et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
43. Vermeulen L., Vanden Berghe W., Haegeman G. Regulation of NF-kappaB transcriptional activity. Cancer Treat Res 2006, 130:89-102.
44. Godwin P., Baird A.-M., Heavey S., Barr M., O'Byrne K., Gately K.A. Targeting Nuclear Factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013, 3.
45. Kim J.K., Kim K.D., Lee E., et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004, 212:61-70.
46. Pal I., Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012, 33:1441-1458.
47. Suzuki Y., Oonishi T., Kudo T., Doi H. LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. Drug Discov Ther 2012, 6:24-30.
48. Gill R., Yang S.H., Meerzaman D., et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011, 30:3784-3791.
49. Matsumoto S., Iwakawa R., Takahashi K., et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007, 26:5911-5918.
50. Wetzker R., Rommel C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 2004, 10:1915-1922.
51. Semba S., Itoh N., Ito M., Harada M., Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res 2002, 8:1957-1963.
52. Vlahos C., Matter W., Hui K., Brown R. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241-5248.
53. Yuan T., Cantley L. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
54. Garcia-Echeverria C., Sellers W. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
55. Folkes A.J., Ahmadi K., Alderton W.K., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008, 51:5522-5532.
56. Salphati L., Pang J., Plise E., et al. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica 2011, 41:1088-1099.
57. O'Brien C., Wallin J., Sampath D., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010, 16:3670-3683.
58. Wagner A.J., Tibes R., Shapiro G.I., Lyengar T., Demetri G.D., Weiss G.J. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Ann Oncol 2010, 21(Suppl. 8).
59. Gonzalez-Angulo A., Blumenschein G. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013, 39:313-320.
60. Genentech. Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer. Clinical Trialsgov [Internet]. Available from: <>: [Accessed 28/04/13], Identifier: NCT01493843; 2011. http://www.clinicaltrials.gov/ct2/show/NCT01493843?term=GDC-0941&rank=10.
61. Howes A.L., Chiang G.G., Lang E.S., et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007, 6:2505-2514.
62. Ihle N.T., Paine-Murrieta G., Berggren M.I., et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005, 4:1349-1357.
63. Ihle N., Lemos R., Wipf P., et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009, 69:143-150.
64. Inc. O. Study of PX-866 and Docetaxel in Solid Tumors. ClinicalTrialsgov [Internet]. Available from: <>: [Accessed 28/04/13], Identifier: NCT01204099; 2010. http://www.clinicaltrials.gov/ct2/show/NCT01204099?term=PX-866&rank=4.
65. Burger M.T., Pecchi S., Wagman A., et al. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2011, 2:774-779.
66. Maira S.-M., Pecchi S., Huang A., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012, 11:317-328.
67. Zheng Y., Yang J., Qian J., et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 2012, 90:695-706.
68. Bendell J., Rodon J., Burris H., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012, 30:282-290.
69. Chakrabarty A., Sanchez V., Kuba M.G., Rinehart C., Arteaga C.L., et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 2012, 109:2718-2723.
70. Salphati L., Heffron T., Alicke B., et al. Targeting the PI3K pathway in the brain-efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res 2012, 18:6239-6248.
71. Nacht M., Qiao L., Sheets M., et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. J Med Chem 2013, 56:712-721.
72. Jia S., Liu Z., Zhang S., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
73. Zheng Z., Miller M., Jennings I., Thompson P. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis. ACS Chem Biol 2013, 8:679-683.
74. Knight Z., Gonzalez B., Feldman M., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
75. Tups A., Anderson G., Rizwan M., et al. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus. J Neuroendocrinol 2010, 22:534-542.
76. Brana I., Siu L. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012, 10:161.
77. Sanofi. A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer. ClinicalTrialsgov. Available from: <>: [Accessed 28/04/13], Identifier: NCT01673737; 2012. http://www.clinicaltrials.gov/ct2/show/NCT01673737?term=SAR260301&rank=1.
78. Lannutti B.J., Meadows S.A., Herman S.E. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Expert Opin Ther Pat 2011, 117:591-594.
79. Norman P. Selective PI3Kδ inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011, 21:1773-1790.
80. Ndubaku C., Heffron T., Staben S., et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor with high unbound exposure and robust in vivo anti-tumor activity. J Med Chem 2013, 4:597-610.
81. Juric D, Krop I, Ramanathan RK, et al. GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. AACR Annual Meeting. Washington DC, 2013.
82. Gridelli C., Maione P., Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008, 13:139-147.
83. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer 2012, 2:52-66.
84. Vansteenkiste J., Solomon B., Boyer M., et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol 2011, 6:2120-2129.
85. Bryce A.H., Rao R., Sarkaria J., et al. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs 2012, 5:1934-1941.
86. Seki Y., Yamamoto N., Tamura Y., et al. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 69:1099-1105.
87. Mita M.M., Mita A.C., Chu Q.S., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008, 26:361-367.
88. Vilar E., Perez-Garcia J., Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011, 10:395-403.
89. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-83.
90. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009, 315:485-497.
91. Prasad G., Sottero T., Yang X. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011, 13:384-392.
92. Inc AP. Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma. ClinitalTrialsgov [Internet]. Available from: <>: [Accessed 28/04/13], Identifier: NCT00698243; 2008. http://www.clinicaltrials.gov/ct2/show/NCT00698243?term=OSI-027&rank=1.
93. Bhagwat S.V., Gokhale P.C., Crew A.P., et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 2011, 10:1394-1406.
94. Wallin J., Edgar K., Guan J., et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011, 10:2426-2436.
95. Genentech. Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy. ClinicalTrialsgov [Internet]. Available from: <>: [Accessed 28/04/13], Identifier: NCT01437566; 2011. http://www.clinicaltrials.gov/ct2/show/NCT01437566?term=GDC-0980&rank=6.
96. Hilgard P., Klenner T., Stekar J., Nossner G., Kutscher B., Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumor activity. Eur J Cancer 1997, 33:442-446.
97. Dasmahapatra G.P., Didolkar P., Alley M.C., Ghosh S., Sausville E.A., Roy K.K. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004, 10:5242-5252.
98. Elrod H.A., Lin Y.D., Yue P., et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007, 6:2029-2038.
99. Richardson P., Eng C., Kolesar J., Hideshima T., Anderson K. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol 2012, 8:623-633.
100. Zentaris A. Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer (X-PECT). Clin Trialsgov [Internet]. [Accessed: 28/04/13], Identifier: NCT010970182010.
101. Yan L. MK-2206: a potent oral allosteric AKT inhibitor. AACR Annual Meeting 2009.
102. Hirai H., Sootome H., Nakatsuru Y., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967.
103. Yap T.A., Yan L., Patnaik A., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695.
104. (NCI) NCI. MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy. Clin Trialsgov [Internet]. [Accessed 28/04/13], Identifier: NCT012943062011.
105. Blake J., Xu R., Bencsik J., et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012, 55:8110-8127.
106. Lin J., Sampath D., Nannini M., et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013, 19:1760-1772.
107. Yan Y., Wagle M., Punnoose E. A firstin-human trial of GDC-0068: a novel, oral, ATP-competitive AKT inhibitor, demonstrates robust suppression of the AKT pathway in surrogate and tumor tissues. Mol Cancer Ther 2011, 12-16.
108. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009, 15:425-430.
109. NCI. Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma. Clin Trialsgov [Internet]. [Accessed 28/04/13], Identifier: NCT000758812044.
110. Mack P.C., Davies A.M., Lara P.N., Gumerlock P.H., Gandara D.R. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003, 41(Suppl. 1):89-96.
111. Chaft J.E., Arcila M.E., Paik P.K., et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012, 11:485-491.
112. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012, 7:1315-1326.
113. Mazières J., Peters S., Lepage B., et al. Lung cancer that harbors a HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 16:1997-2003.
114. Nelson V., Ziehr J., Agulnik M., Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets Ther 2013, 6:135-143.
115. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A., Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006, 118:209-214.
116. Li H., Schmid-Bindert G., Wang D., et al. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 2011, 56:275-284.
117. Eichhorn P., Gili M., Scaltriti M., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
118. Dong S., Zhang X.C., Cheng H., et al. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2012, 5:707-716.
119. Tan DSW, Lim KH, Tai WM, et al. A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC. Abstract 8107. 2013 ASCO Annual Meeting 2013.
120. Adjei A.A. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clin Lung Cancer 2005, 7:221-223.
121. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
122. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004, 22:4456-4462.
123. Hersey P., Bastholt L., Chiarion-Sileni V. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009, 20(Suppl. 6):vi35-40.
124. Center MDAC. BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study. Clin Trialsgov [Internet]. [Accessed 28/04/13], Identifier: NCT012482472010.
125. Sos M.L., Fischer S., Ullrich R., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA. 2009, 106:18351-18356.
126. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
127. Mirzoeva O.K., Das D., Heiser L.M., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
128. Hoeflich K.P., O'Brien C., Boyd Z., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664.
129. Zou Z.Q., Zhang L.N., Wang F., Bellenger J., Shen Y.Z., Zhang X.H. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Rep 2012, 5:503-508.
130. Pharmaceuticals N. Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients. Clini Trialsgov [Internet]. [Accessed 28/04/13], Identifier: NCT013632322011.
131. Schuurbiers O., Kaanders J., van der Heijden H., Dekhuijzen R., Oyen W., Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009, 4:761-767.
132. Toulany M., Dittmann K., Krüger M., Baumann M., Rodemann H. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 2005, 76:143-150.
133. Brognard J., Clark A., Ni Y., Dennis P. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986-3997.
134. Kim T.J., Lee J.W., Song S., et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006, 94:1678-1682.
135. Toulany M., Kasten-Pisula U., Brammer I., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 2006, 12:4119-4126.
136. Gottschalk A., Doan A., Nakamura J., Stokoe D., Haas-Kogan D. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Biol Oncol Phys 2005, 63:1221-1227.
137. Lee C., Fuhrman C., Planelles V., et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006, 12:250-256.
138. Kolasa I., Rembiszewska A., Felisiak A., et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009, 1:21-26.
139. Lee S., Choi E.-J., Jin C., Kim D.-H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97:26-34.
140. Wu H., Cao Y., Weng D., et al. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008, 271:260-271.
141. Yan X., Fraser M., Qiu Q., Tsang B. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 2006, 102:348-355.
142. Asechi H., Hatano E., Nitta T. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 2010, 37:89-96.
143. Grotegut S., Kappler R., Tarimoradi S., Lehembre F., Christofori G., Von Schweinitz D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol 2010, 36:1261-1267.
144. Yoon H., Min J.-K., Lee J., Kim D.-G., Hong H. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun 2011, 405:333-337.
145. Johnson-Holiday C., Singh R., Johnson E., Grizzle W., Lillard J., Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol 2011, 9:46.
146. Wong S., Tiong K., Kong W., et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011, 128:301-313.
147. Zhang W., Ding W., Chen Y., et al. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43:647-653.
148. Liu Z., Sun C., Zhang Y., Ji Z., Yang G. Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma. J Int Med Res 2011, 39:1319-1332.
149. Yoshida T., Miyoshi T., Seike J.-I., et al. Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray. Anticancer Res 2009, 29:1163-1168.
150. Tsurutani J., West K., Sayyah J., Gills J., Dennis P. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005, 65:8423-8432.
151. Dhar R., Basu A. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. Int J Oncol 2008, 32:1133-1137.
152. Kuroda H., Takeno M., Murakami S., Miyazawa N., Kaneko T., Ishigatsubo Y. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 2010, 67:31-36.
153. Xu J.L., Wang Z.W., Hu L.M., et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-BASED chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev 2012, 13:2157-2162.
154. Haidinger M., Poglitsch M., Geyeregger R., et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010, 185:3919-3931.
155. Webb L., Vigorito E., Wymann M., Hirsch E., Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005, 175:2783-2787.
156. Hemon P., Jean-Louis F., Ramgolam K., et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011, 186:5173-5183.
157. Noh K., Kang T., Kim J., et al. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 2009, 17:439-447.
158. Nicolini A., Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 2009, 29:436-471.
159. Whiteside T. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16:3-15.
160. Szajnik M., Czystowska M., Szczepanski M., Mandapathil M., Whiteside T. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PloS One 2010, 5.
161. Dituri F., Mazzocca A., Giannelli G., Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol 2011, 2011:947858.
162. Zheng Y., Collins S., Lutz M., et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007, 178:2163-2170.
163. + regulatory T cells. Blood 2005, 105:4743-4748.
164. Delgoffe G., Kole T., Zheng Y., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
165. Zeng H., Yang K., Cloer C., Neale G., Vogel P., Chi H. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 2013, 499:485-490.
166. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007, 178:7018-7031.
167. Freeman G., Long A., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
168. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-347.
169. Brahmer J., Tykodi S., Chow L., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
170. Lastwika K, Wilson W, Denis PA. PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC (Abstract 4981). AACR Annual Meeting 2013.
171. Marshall N., Galvin K., Corcoran A.-M.B., Boon L., Higgs R., Mills K. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res 2012, 72:581-591.